PsyNews.com

This Vital Community webinar introduces an emerging sub-threshold psilocybin protocol developed within a trauma-informed, parts-based therapeutic framework. This approach adapts the principles of low-dose...

At the Psychedelic Healthcare Forum, which took place in New York City last Thursday and was co-hosted by Psychedelic Alpha, a panel of federal...

At The Psychedelic Healthcare Forum that we co-hosted last Thursday in New York, our Editor Josh Hardman sat down with Matt Zorn, Deputy General...

Post Content

FDA laid out how the first federally funded ibogaine trials could be run, with inpatient cardiac monitoring and a 10 mg/kg starting dose ceiling....

A symptom scale can show that someone feels better after a psychedelic experience. Behavior analyst Gianna Biscontini argues that integration should also track what...

Post Content

On Monday, the day FDA’s Considerations for Potential Future Therapeutic Use of Psychedelic Drugs public comment period closed, the agency issued a request for...

Kenneth Tupper joins Joe Moore for a wide-ranging conversation on harm reduction, drug education, British Columbia’s toxic drug crisis, ayahuasca policy, entheogenic education, and...

A DEA judge has paused the hearing on moving all marijuana to Schedule III while he decides whether to admit a GAO report on...

Post Content

The psychedelic field has built institutions for studying molecules, delivering therapies, and training facilitators. Paul Ryder, founder of the Congregation for Sacred Practices, argues...